EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RANK is a poor prognosis marker and a therapeutic target in ER ‐negative postmenopausal breast cancer

Marina Ciscar, Eva M Trinidad iD, Gema Perez-Chacon iD, Mansour Alsaleem iD, Maria Jimenez iD, Maria J Jimenez-Santos, Hector Perez-Montoyo iD, Adrian Sanz-Moreno iD, Andrea Vethencourt, Michael Toss iD, Anna Petit, Maria T Soler-Monso und 14 weitere

EMBO Molecular Medicine · 2023

DOI: 10.15252/emmm.202216715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Marina Ciscar und 25 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, European Research Council, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor‐negative, ER − ) from four independent cohorts. RANK protein expression was more frequent in ER − tumors, where it associated with poor outcome and poor response to chemotherapy. In ER − breast cancer patient‐derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER − breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK + ER − tumors after menopause.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFemaleHumansDenosumabReceptor Activator of Nuclear Factor-kappa BPostmenopauseRANK LigandSignal Transduction

Stichwörter der Autor:innen

ER negative breast cancerRANK-RANKLbreast cancer patient-derived xenograftsmenopausepharmacological RANKL inhibitors

Substanzen

DenosumabReceptor Activator of Nuclear Factor-kappa BRANK Ligand

Autor:innen und Institutionen

  • Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Nottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham, UK.
  • Bioinformatics Unit, Structural Biology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Medical Oncology, Breast Unit, Catalan Institute of Oncology (ICO), University Hospital of Bellvitge, Barcelona, Spain.
  • Pathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.

ORCID-Profile: Eva M Trinidad, Gema Perez-Chacon, Mansour Alsaleem, Maria Jimenez, Hector Perez-Montoyo, Adrian Sanz-Moreno, Michael Toss, Jorge Gomez-Miragaya, Lacey E Dobrolecki, Michael T Lewis, Andrew R Green, Eva Gonzalez-Suarez

Förderung

  • NCI NIH HHS
  • European Research Council
  • Instituto de Salud Carlos III
  • Ministerio de Ciencia e Innovación

Zitieren

APA

Ciscar, M., Trinidad, E. M., Perez-Chacon, G., Alsaleem, M., Jimenez, M., Jimenez-Santos, M. J., Perez-Montoyo, H., Sanz-Moreno, A., Vethencourt, A., Toss, M., Petit, A., Soler-Monso, M. T., Lopez, V., Gomez-Miragaya, J., Gomez-Aleza, C., Dobrolecki, L. E., Lewis, M. T., Bruna, A., Mouron, S., …, & Gonzalez-Suarez, E. (2023). RANK is a poor prognosis marker and a therapeutic target in ER ‐negative postmenopausal breast cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216715

Vancouver

Ciscar M, Trinidad EM, Perez-Chacon G, Alsaleem M, Jimenez M, Jimenez-Santos MJ, et al. RANK is a poor prognosis marker and a therapeutic target in ER ‐negative postmenopausal breast cancer. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202216715

BibTeX
@article{Ciscar2023,
  author = {Ciscar, Marina and Trinidad, Eva M and Perez-Chacon, Gema and Alsaleem, Mansour and Jimenez, Maria and Jimenez-Santos, Maria J and Perez-Montoyo, Hector and Sanz-Moreno, Adrian and Vethencourt, Andrea and Toss, Michael and Petit, Anna and Soler-Monso, Maria T and Lopez, Victor and Gomez-Miragaya, Jorge and Gomez-Aleza, Clara and Dobrolecki, Lacey E and Lewis, Michael T and Bruna, Alejandra and Mouron, Silvana and Quintela-Fandino, Miguel and Al-Shahrour, Fatima and Martinez-Aranda, Antonio and Sierra, Angels and Green, Andrew R and Rakha, Emad and Gonzalez-Suarez, Eva},
  title = {RANK is a poor prognosis marker and a therapeutic target in ER ‐negative postmenopausal breast cancer},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  doi = {10.15252/emmm.202216715}
}
Kostenlos starten →